<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-8334321271827217759</id><updated>2026-11-21T14:22:14.688-08:00</updated><category term="FDA"/><category term="digital health"/><category term="telemedicine"/><category term="Evidence-based medicine"/><category term="dhealth"/><category term="telehealth"/><category term="EBM"/><category term="CLFS"/><category term="PAMA"/><category term="clinical laboratory fee schedule"/><category term="gapfill"/><category term="ldt"/><category term="ngsncd"/><category term="zheartflow"/><category term="ALJ"/><category term="CMS"/><category term="Genomics"/><category term="HTA"/><category term="Medicare"/><category term="Risk/Benefit"/><category term="crosswalk"/><category term="fda ldt"/><category term="health technology assessment"/><category term="panels"/><category term="telepathology"/><category term="z70percent"/><category term="zai"/><category term="zdecisionimpact"/><category term="zliquidbiopsy"/><category term="&quot;digital health&quot;"/><category term="&quot;precision medicine initiative&quot; pmi"/><category term="&quot;site neutral&quot; &quot;bipartisan budget act&quot; &quot;section 603&quot; avalere"/><category term="&quot;tier 2&quot;"/><category term="#covid"/><category term="#serology"/><category term="14dayrule"/><category term="2019"/><category term="21cc"/><category term="510k"/><category term="8122"/><category term="CDS"/><category term="DRG"/><category term="FDASIA"/><category term="Genomics industry"/><category term="Guidelines"/><category term="OIG"/><category term="OMHA"/><category term="Personalized medicine"/><category term="Prior Authorization"/><category term="ama"/><category term="anthem"/><category term="backlog"/><category term="brca"/><category term="bundling"/><category term="ced"/><category term="chronic care"/><category term="clingen"/><category term="clinical decision support"/><category term="clinical utility"/><category term="clsf"/><category term="cmmi"/><category term="cmmi diabetes demonstration dpp diabetes prevention program"/><category term="cologuard"/><category term="daia"/><category term="decision impact"/><category term="denovo"/><category term="dhealth genomics futurism"/><category term="dhig"/><category term="dtc"/><category term="equity"/><category term="exact sciences"/><category term="fmi"/><category term="forgotten"/><category term="gao"/><category term="gobeille scotus &quot;big data&quot;"/><category term="hearttransplant"/><category term="hill"/><category term="ldtivd"/><category term="lilly"/><category term="medicaidization narrownetworks narrow networks zoon"/><category term="medical software"/><category term="moldx"/><category term="myriad"/><category term="oon"/><category term="pama auc lbm"/><category term="panel"/><category term="pqri"/><category term="pqrs"/><category term="precision medicine"/><category term="projectindy"/><category term="psa"/><category term="reimbursement"/><category term="reportlanguage"/><category term="ruc"/><category term="rwe"/><category term="senate finance committee"/><category term="sep1"/><category term="sfc"/><category term="statistics"/><category term="support"/><category term="surprisebilling&#xa;tagtelemedicine"/><category term="tagced"/><category term="tagssa"/><category term="tagsurprisebilling"/><category term="theranos"/><category term="transmittal"/><category term="valid"/><category term="value-based healthcare"/><category term="z21cc"/><category term="zama"/><category term="zamp zguidance zconcordance"/><category term="zartificialintelligence"/><category term="zauc zpama"/><category term="zbreakthrough"/><category term="zcaptoday"/><category term="zced"/><category term="zcmmi"/><category term="zcrc"/><category term="zcriticalracetheory"/><category term="zdhealth"/><category term="zdigitalgenomics"/><category term="zdigitalpathology"/><category term="zequity"/><category term="zexclusions"/><category term="zgapfill"/><category term="zgenetics"/><category term="zhearttransplant"/><category term="zmedicare"/><category term="zmendel"/><category term="zmfi"/><category term="zoig"/><category term="zrady"/><category term="zruc"/><category term="zscreening"/><category term="zsolvebio"/><category term="zstatistics"/><category term="zurbanmyth"/><category term="zvalid&#xa;zamp"/><title type='text'>Discoveries in Health Policy</title><subtitle type='html'>Ideas for or from an evolving healthcare system</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='https://www.discoveriesinhealthpolicy.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default?start-index=26&amp;max-results=25'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>3617</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-5205055174176970634</id><published>2026-11-20T11:39:19.210-08:00</published><updated>2026-11-20T11:40:29.885-08:00</updated><title type='text'>United Health Care Undergoes Audit of its Medical Policy Development Process</title><summary type="text">United Healthcare has released a detailed report - by FTI and Rubrum Consulting - on how its medical policies and evidence reviews stack up.&amp;nbsp;&amp;nbsp;## ##UnitedHealthcare Opens Its Medical Policy Process to Independent ReviewA review of how coverage policies are madeUnitedHealth Group has released an independent review of UnitedHealthcare’s medical policy development process. Commissioned by </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/5205055174176970634'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/5205055174176970634'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/united-health-care-undergoes-audit-of.html' title='United Health Care Undergoes Audit of its Medical Policy Development Process'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-8533182644878625238</id><published>2026-11-19T16:52:40.662-08:00</published><updated>2026-11-20T09:07:48.229-08:00</updated><title type='text'>FDA Publishes Regulatory Approach to AI for Cytology</title><summary type="text">Participants to the May 2026 AMA CPT in Boston may recall that Hologic proposed a code for AI Cytology, but the AMA CPT committee rejected it because there was already a decades-old code for computer-assisted cytology, after which they turned back to painting bison on the walls with chalk.FDA is moving forward, and has just published final paperwork for AI-assisted cervical cytology.&amp;nbsp;&amp;nbsp;</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/8533182644878625238'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/8533182644878625238'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/fda-publishes-regulatory-approach-to-ai.html' title='FDA Publishes Regulatory Approach to AI for Cytology'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-8991568589559525043</id><published>2026-11-19T09:43:24.902-08:00</published><updated>2026-11-20T12:27:46.597-08:00</updated><title type='text'>USPSTF - It&#39;s Baaaack!   From GAO to Agenda...</title><summary type="text">&amp;nbsp;USPSTF Back in Business After 20 Months;&amp;nbsp;AHRQ Director Envisions AI-Driven Evidence Reviews; GAO Finds AHRQ Funding Impoundment Illegal&amp;nbsp;Chat GPT 6, November 20, 2026 (Los Angeles).&amp;nbsp; Exclusive to: Discoveries in Health Policy.After an extraordinary 20-month hiatus, the U.S. Preventive Services Task Force (USPSTF) reconvened on November 19–20, 2026. The meeting is noteworthy </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/8991568589559525043'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/8991568589559525043'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/uspstf-its-baaaack-agenda-nov-19-20-2026.html' title='USPSTF - It&#39;s Baaaack!   From GAO to Agenda...'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhmyi4_123lE0NzYtSkvb7OASybPhrajnI3jOsziZKpPmvQEY01DZUddsqzrcPUx6SjHqwyivqsy7vm2vxdnLVMoauwonDfyR41Qnc29L7xSd73DrrXBpyW-29iS_QCAOexYWb9OGSYHfx_23zkRWdG4eB4_7sFEL8ykFsfpSFscGDgIO7DzCmOXKxsbnQ/s72-w475-h267-c/AI-Accelerated%20Evidence%20Review.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-2775649485163964441</id><published>2026-11-18T19:00:06.792-08:00</published><updated>2026-11-18T19:42:41.590-08:00</updated><title type='text'>Will Analogies Speed You Through Regulators?  Through Coverage?</title><summary type="text">Using health technology as an example, a new article in Harvard Business Review gives data-based tips on how to succeed with regulators - and some may apply to payers as well.The original article is Pahnke et al. in Strategic Management Journal:&amp;nbsp;&amp;nbsp;Strategic positioning and accelerating regulatoryclearance for new ventures,&amp;nbsp;here.&amp;nbsp; &amp;nbsp;It&#39;s covered and summarized in Harvard </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/2775649485163964441'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/2775649485163964441'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/will-analogies-speed-you-through.html' title='Will Analogies Speed You Through Regulators?  Through Coverage?'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhO2ISG5-EbiRtsmyEw1TnTrYXgc8zXO6laFY9yOOux_-f3OuUkYGyKxs_ZceWovJeLR6olhaZa7HwHyXa01ZOZTQ4yns71ZkgnluJzan_DxooxJg5u94P5ZmbbofbwFVij4Y0GnEHgMAaPvhZgRrcZHcnpMHLGmNF-1TH_MP_090oSi04I3GNltMnDURk/s72-w459-h260-c/image.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-4732801974001040609</id><published>2026-11-18T09:48:12.994-08:00</published><updated>2026-11-18T09:52:18.359-08:00</updated><title type='text'>AMA CPT for February 4-6, Lab Codes Posted for Early Comment</title><summary type="text">&amp;nbsp;AMA CPT hasn&#39;t yet posted registration for the February 2027 Los Angeles AMA CPT.https://www.ama-assn.org/membership/events/cpt-editorial-panel-meetingBut they&#39;ve posted the lab applications, which go through early comment due ot their special subcommittees.Lab codes are here:https://www.ama-assn.org/system/files/february-2027-lab-agenda.pdfRequests to review and comment - see the blue Link</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/4732801974001040609'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/4732801974001040609'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/ama-cpt-for-feburary-2-4-lab-codes.html' title='AMA CPT for February 4-6, Lab Codes Posted for Early Comment'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-549067785036477221</id><published>2026-11-18T08:28:18.999-08:00</published><updated>2026-11-18T14:26:51.801-08:00</updated><title type='text'>Trop2 as Oncology Companion Diagnostic: Pivotal Paper from Garassino et al.</title><summary type="text">&amp;nbsp;We&#39;ve been hearing for a couple years that important new antibody-payload drugs will need IHC diagnostics, rather than the genomic ones we&#39;re used to (KRAS, etc).Now we have a pivotal paper about the diagnostic TROP2 for datroway / datopotamab deruxtecan.&amp;nbsp; See Garassino et al, Nature Medicine, November 11, 2027.Key CDx point:&amp;nbsp; They tried regular scoring 1+ 2+ 3+, and it didn&#39;t </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/549067785036477221'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/549067785036477221'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/trop2-as-oncology-companion-diagnostic.html' title='Trop2 as Oncology Companion Diagnostic: Pivotal Paper from Garassino et al.'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEii_W7ZOovrWWYkPInnqUE6pOa8tLUAnD4jmzeXTGlI222X5VyOkl4J6Nd02Or9aNp6ShPj1qb2pzkuht7-_kDkF3l86ttREiGq1ueDyxZTbYn4wK2Mf6DpkwGMEuK5_56PjzWcZCoA8Yem4-D3iuruQ7KDKy8QprljMZuf387oE0LONOgSawwy4BrQK9E/s72-w396-h221-c/image.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-5473657167194714433</id><published>2026-11-18T07:56:45.718-08:00</published><updated>2026-11-19T13:20:25.406-08:00</updated><title type='text'>AMA November 20:  Town Hall on Defining &quot;Widespread Use&quot;</title><summary type="text">&amp;nbsp;One of the trickiest gates between you and a new AMA CPT code is &quot;widespread use.&quot;&amp;nbsp; AMA deliberately doesn&#39;t define it, because 400 cases per year of 1000 possible is &quot;widespread&quot; use, but 4000 cases per year of 1M possible may not be &quot;widespread&quot; use.&amp;nbsp; &amp;nbsp;(Also, AMA prefers to gate new codes to services in widespread use to allow an immediate and large enough RUC valuation </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/5473657167194714433'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/5473657167194714433'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/ama-november-20-town-hall-on-defining.html' title='AMA November 20:  Town Hall on Defining &quot;Widespread Use&quot;'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-3604424961696704580</id><published>2026-11-17T09:09:05.019-08:00</published><updated>2026-11-18T14:36:10.755-08:00</updated><title type='text'>Geneoscopy, Exact Sciences: All Patent Claims Settled (&quot;Obviousness&quot;)</title><summary type="text">On November 17, 2026, a press release from Geneoscopy announces the settlement of claims and counterclaims between the two companies.Pivotal steps along the legal pathway were PTO rulings that two major Exact patents, &#39;746 and &#39;781, failed a judicial review for &quot;obviousness.&quot;&amp;nbsp; &amp;nbsp;Obviously, the same patents had passed their patent reviews.&amp;nbsp; What changed?&amp;nbsp; What was most important</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/3604424961696704580'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/3604424961696704580'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/geneoscopy-exact-sciences-all-patent.html' title='Geneoscopy, Exact Sciences: All Patent Claims Settled (&quot;Obviousness&quot;)'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-1741249631770572648</id><published>2026-11-16T14:05:51.915-08:00</published><updated>2026-11-16T18:05:33.625-08:00</updated><title type='text'>CMS RELEASES &quot;CRUSH&quot; ANTI FRAUD RULE:  ZIPPO RE LABS</title><summary type="text">CMS has released a proposed version of its new anti fraud CRUSH rules.&amp;nbsp; While the roll-out seemed to be &quot;half DME and half lab industry,&quot; the proposed rule hardly mentions the word &quot;laboratory.&quot;Press:https://www.cms.gov/newsroom/press-releases/cms-crush-proposed-rule-aims-reap-nearly-90-billion-taxpayers-savings-targeting-fraud-acrossFAQ:https://www.cms.gov/newsroom/fact-sheets/</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/1741249631770572648'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/1741249631770572648'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/cms-releases-crsh-anti-fraud-rule-zippo.html' title='CMS RELEASES &quot;CRUSH&quot; ANTI FRAUD RULE:  ZIPPO RE LABS'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-7033256667472602391</id><published>2026-11-16T09:59:18.814-08:00</published><updated>2026-11-16T14:31:25.975-08:00</updated><title type='text'>CMS Publishes Template for Uses of SUPER INTELLIGENCE in Medicare, Medicaid</title><summary type="text">Recall that recently, HHS ordered that HHS, CMS, NIH, FDA, all use &quot;SUPER INTELLIGENCE&quot; rather than artificial intelligence.&amp;nbsp; My blog.We&#39;ve now got a brand new 8 page report on how cMS wants to use SUPER INTELLIGENCE to lower costs while giving better answers and faster care.&amp;nbsp; And it&#39;s getting some press.Find the 8 page white paper here:https://www.cms.gov/files/document/</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7033256667472602391'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7033256667472602391'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/cms-publishes-template-for-uses-of.html' title='CMS Publishes Template for Uses of SUPER INTELLIGENCE in Medicare, Medicaid'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-7521345088723737436</id><published>2026-11-16T09:37:16.738-08:00</published><updated>2026-11-18T08:01:35.283-08:00</updated><title type='text'>FDA Downclassifies Again: IHC for CDx</title><summary type="text">Update: See also Kelly Gordon&#39;s Linked In article here.# # #I posted a blog on September 3, 2026, that FDA had recently downclassified oncology cDx with ISH or FISH from&amp;nbsp; Class III (PMA) to Class II (e.g. 510k or de novo 510k).&amp;nbsp; At the time, the news was two weeks old but had gotten very little press.Now, in November, similar news for a much larger area, CDx with&amp;nbsp;IHC, </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7521345088723737436'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7521345088723737436'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/fda-downclassifies-again-from-ish-to.html' title='FDA Downclassifies Again: IHC for CDx'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgzooWKY1EF9rXtiBk1yb1Z9PnhF6-yDJdGTSM1Xb3w6lnr0V7N3D0Ip1Qd9VTZx2VBgpnYTp7x4Ckjc17zrgsiYsh6dIvp6m22lCgc2vpcrOebOBWeUdKT_IF6X_W63gYIgK_94QcUKtPu_nILZQZAgjWUvgPelBHjbyTQOz6guibjynxMSu56gpb38zE/s72-w524-h234-c/image.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-5838651966848529977</id><published>2026-11-16T09:20:31.421-08:00</published><updated>2026-11-18T09:36:43.829-08:00</updated><title type='text'>Using AI at my Desk at Work:  A Weekly Agentic Search for AI Report Generation Advances (Radiology or Pathology)</title><summary type="text">Each Monday, I used &quot;agentic AI&quot; to run a complex scheduled AI search in Chat GPT.&amp;nbsp; The topic is new publications related to generating either Radiology or Pathology reports by AI, including news about FDA reviews, etc.&amp;nbsp; (It also tracks the FDA K260303 web page).##Here is a cut/paste out of what it delivered to me for November 16, 2026.&amp;nbsp; Note that at bottom, I also gave it a link </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/5838651966848529977'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/5838651966848529977'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/using-ai-at-my-desk-at-work-weekly.html' title='Using AI at my Desk at Work:  A Weekly Agentic Search for AI Report Generation Advances (Radiology or Pathology)'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-1469122382721457999</id><published>2026-11-12T12:14:05.830-08:00</published><updated>2026-11-12T12:14:05.830-08:00</updated><title type='text'>Two Authors, Two Books on Digital Pathology</title><summary type="text">&amp;nbsp;This week, I ran across two authors on Linked In who have each written a book that introduces the world of digital pathology.The first author is Dr. Aleks Zuraw.&amp;nbsp; Her book is a take-home associated with a webinar she is giving this week.&amp;nbsp; &amp;nbsp;&quot;Digital Pathology 101, 2nd Edition.&quot;&amp;nbsp; Find registration here:https://lnkd.in/p/grdGQianandhttps://lnkd.in/p/gVByAMuS####The second </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/1469122382721457999'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/1469122382721457999'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/two-authors-two-books-on-digital.html' title='Two Authors, Two Books on Digital Pathology'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgyTGo8EyB6e4i0JVtSE74jfBQtkLrq0VfYvWtfx79riSiOqgqGic1K_eaAzMj4mRfJDwtJFOkYVBwPuXsShV-T8kcISDrHy2hago_MtyAvl-AlypViQyMWFAA7T49VQsYKepoSMII6FqBWAKQ_A6ubLBIVOcBRFQtILcKRUzi7sOa542lZqQoyoFeienk/s72-w391-h505-c/COVER%20TWO%20BOOKS.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-6035554518587654763</id><published>2026-11-12T08:03:19.424-08:00</published><updated>2026-11-15T21:23:06.761-08:00</updated><title type='text'>Brief Blog:  How CMS Updates Products Covered Under NCDs</title><summary type="text">A brief update on how CMS covers products that are covered by definition, under an NCD.&amp;nbsp;&amp;nbsp;The example here is NCD 90.2, Uses of NGS in Cancer.&amp;nbsp; &amp;nbsp;FDA cleared-or-approved companion diagnostics are covered by this NCD for on-label uses.&amp;nbsp; &amp;nbsp;Often, this means PMA CDx approval for one or more indications (gene-drug), and a secondary FDA label which is for profiling mutations</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/6035554518587654763'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/6035554518587654763'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/brief-blog-how-cms-updates-products.html' title='Brief Blog:  How CMS Updates Products Covered Under NCDs'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi4b71IsUlYwylNQb4Hql5kp86UJcw4uYLJD_s1PgPeOcSCyxNQxfmDl9K2ed1AYbkhsk9uPsBrkfEme9fOg56-ZEfGc3o3NPfswHp-2d2mtP8OepMDI3IidALRvs6hKqBZ3hwOpPdzyMS_PybOBziiqavn5UeJnwhaJiuscV44seizbZicjb6MFpXXX1k/s72-c/image.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-6701021610124349270</id><published>2026-11-11T00:40:33.625-08:00</published><updated>2026-11-11T00:58:28.136-08:00</updated><title type='text'>PAMA: The Secret Data Views that CMS Never Displays (for GSP Genomic Sequencing Procedures)</title><summary type="text">Medicare genomic sequencing pricing under PAMA is based on anywhere from 200 to 275,000 claims for the &quot;GSP&quot; service type.&amp;nbsp; &amp;nbsp;For Exome and Genome, a large body of claims were paid at about half the Medicare CLFS rate.Note that none of this data is Medicare data; it&#39;s private payer data...the behavior of private payers###Goodbye to a myth?Are CMS CLFS prices a benchmark that strongly </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/6701021610124349270'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/6701021610124349270'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/pama-secret-data-views-that-cms-never.html' title='PAMA: The Secret Data Views that CMS Never Displays (for GSP Genomic Sequencing Procedures)'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIEL_Rvsh3UfwB4neLxqFj5tu-T1bqh_1yQyLV-uYiEWK7yJEnB69AdHqKAVa6W8h4hmoYHTokT5nIx4TCJgSFd9gppqUA0yfge3zVjGDSm_9S60goHn4LIwG_YHgDbn8bH1nQGBRcHdPhu7VFpnZ4ZDYwAm-DRfSAX2ybt4O3GZ2PQi1eVkP0yIr_JLM/s72-w457-h392-c/PAMA_price_distributions_CLFS_stars.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-3736850322571367513</id><published>2026-11-10T16:20:04.257-08:00</published><updated>2026-11-11T00:43:02.301-08:00</updated><title type='text'>Devil in the Details; Understanding GeneDx&#39;s Earning Shocks via Reimbursement</title><summary type="text">&amp;nbsp;GeneDx Earnings Calls Show Why Reimbursement Determines the Economics of Genomic TestingGeneDx’s May earnings shock (down 50%) exposed the financial consequences of a rapid shift toward genome sequencing. Its August and November calls trace the response: manage test mix, expand coverage, and improve collections. The latest results show progress, alongside a practical tradeoff between </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/3736850322571367513'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/3736850322571367513'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/devil-in-details-understanding-genedxs.html' title='Devil in the Details; Understanding GeneDx&#39;s Earning Shocks via Reimbursement'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-7258875963028703640</id><published>2026-11-08T19:50:24.817-08:00</published><updated>2026-11-09T04:30:14.552-08:00</updated><title type='text'>Chris Klomp: #2 at HHS, Update on his Views and Priorities for CMS</title><summary type="text">HEADER.&amp;nbsp; Chris Klomp is about to become the official #2 at HHS - the Deputy Secretary.&amp;nbsp; How does Klomp think Medicare should pay for innovation? His recent WSJ interview and two Senate hearings offer revealing answers: reward outcomes, make clinical AI reduce costs, and align FDA and CMS evidence expectations earlier. But the details matter: RAPID excludes laboratory tests, and senators</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7258875963028703640'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7258875963028703640'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/chris-klomp-2-at-hhs-update-on-his.html' title='Chris Klomp: #2 at HHS, Update on his Views and Priorities for CMS'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9PoNvUHU7U_ZK6-BP5LSyRPr2dA_ATLYv4n8_DZhZ0_STz8gGV-t9m1hXEFyfBhd8bT-r79Dq5GWqzlmkp_ZgKHcC44VzOlNqaJhyphenhyphensTH0yMUR52nrUmzQX-oKCmuv61WejMobecmLcDjmvb0yn3yZlf9-u2zJSHOV2MCQy6_YTDSn4aSewbqS7EpgMfE/s72-w496-h338-c/image.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-1594247574596293038</id><published>2026-11-07T17:44:53.467-08:00</published><updated>2026-11-08T13:30:50.642-08:00</updated><title type='text'>AI Guest Faculty: Lessons from 1870s for Growth of Genomics Today</title><summary type="text">&amp;nbsp;What can the rise of Germany’s synthetic-dye industry in the 1800s teach us about American genomics today?Johann Peter Murmann’s fascinating historical research, followed by a 2016 computer simulation, offers an unexpected starting point.My new white paper explores how scientific talent, capital markets, and Medicare reimbursement shape industrial winners and losers. One intriguing question</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/1594247574596293038'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/1594247574596293038'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/ai-guest-faculty-lessons-from-1870s-for.html' title='AI Guest Faculty: Lessons from 1870s for Growth of Genomics Today'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhHhbWQpoVn0mKMLSqIsqUo6UlfP2PZLDOOHkmZa5SgeZzpBPPnEyHj-hYsCgPLMop7BABImeOdVGr2W4oEbl7kuNd_1Q7wsGyzgNatAHLCMhBPXNSKskwbCPxftec9BN9KtovM2sZ6KLD4DQMOhCZyz2hLfQ7xcRWkfkLfRNPYYi9Hibkx9BJxmnN02YA/s72-w447-h581-c/20240116%20COVER%20JPEG.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-3020415557459123370</id><published>2026-11-06T13:42:05.083-08:00</published><updated>2026-11-09T04:32:45.736-08:00</updated><title type='text'>Three Companies: Investor Calls for Tempus AI, Caris, and Natera, Quarter to Quarter</title><summary type="text">Tempus, Caris, and Natera see enormous opportunity in genomics—but reimbursement determines the pace. Our new AI-generated white paper compares November earnings calls with prior-quarter expectations, examining MolDX coverage, payer pricing, clinical evidence, and promises still awaiting payment.Here&#39;s a summary:Tempus AI, Caris, and Natera report strong demand for genomic testing, but </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/3020415557459123370'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/3020415557459123370'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/three-companies-investor-calls-for.html' title='Three Companies: Investor Calls for Tempus AI, Caris, and Natera, Quarter to Quarter'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEipXTX2uZm4eny51jlLNEYlY1gBiXY6uJebU1nWAIBKI4jz69Q0DdE1TBl4LwACjajor72z0FuV00ankKXYrCKk0QjdGo9pbQc9SUFkJy5QXzHONtCxo9Y_v4j9f0GkH9RhMkypd3OO6q6BG_tk14znFkThnRDtuJORIQRlS_4aP3GwP7z9aEb3bMGiBsA/s72-w447-h579-c/Laboratory%20cover%20with%20Chat%20GPT%206.1%20%20AS%20BOOK%20HA%20HA.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-7038742412891665648</id><published>2026-11-06T08:48:38.839-08:00</published><updated>2026-11-09T04:51:28.325-08:00</updated><title type='text'>Why a Strong Diagnostic Test May Add Little New Information</title><summary type="text">&amp;nbsp;#Why a Strong Diagnostic Test May Add Little &quot;New&quot; Information[Chat GPT 6]My colleague Luis Cano recently posted a useful example of a question that diagnostic developers should ask much earlier: What does the new technology add to what we already know?His post described a pancreatic neuroendocrine tumor preprint involving 1,438 patients and approximately 30,000 histology images. An AI </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7038742412891665648'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/7038742412891665648'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/why-strong-diagnostic-test-may-add.html' title='Why a Strong Diagnostic Test May Add Little New Information'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEidxeCaS9kQkMEMu2zNGzzob8X__PvgdlzzSKVgmYoKtNLPTF6jFcbcXaiYsDTaZmY-rCdsCtte_YakmQBaT_lx7OWjhc3cizjLUldDc6tXh0idu3B8FDdc_q1c38pGYA-B4qAgGBiXFVDycOcaSJiFOO-FCvAtvwhLUgWyjRsiunPbvmYJdL6v26-P0rY/s72-w579-h325-c/2%20What%20the%20Test%20Adds.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-2866649221622873677</id><published>2026-11-05T14:51:20.912-08:00</published><updated>2026-11-05T17:13:36.152-08:00</updated><title type='text'>The Genomics Consulting Book Guide to CLAUDE</title><summary type="text">If this looks familiar, I posted at Linked In&amp;nbsp; about November 1, but not here at the DIHP blog.They Infest Linked InLately, every day Linked In has been offered me &quot;McKinsey Guide to CLAUDE,&quot; &quot;Consultant&#39;s Guide to CLAUDE.&quot;&amp;nbsp; Usually the exciting-sounding offers dead end at a registration page and sign in with your email.Steve Jobs Got His Best Ideas Walking, TooWalking home from lunch </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/2866649221622873677'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/2866649221622873677'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/the-genomics-consulting-book-guide-to.html' title='The Genomics Consulting Book Guide to CLAUDE'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg-R_Sa-5ix3Hdctt-FP4XE5i52MxvUD7MQvIwo3y8XrRc4doFGLC_mytLVy_xpym00bLGHeV69jMJDMmEAOctj1CfodKmH-NJ7yFsgyANs0vVdHtwxtafydkD9yXsdEaBKW5TPx9pxUw7eLgz4pxB8kg9bFhajwepBbgY76mAq2BDpumLGmUfOrrlgUME/s72-w429-h243-c/similar%20guides%20to%20claude.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-8689745595459448191</id><published>2026-11-04T22:18:33.244-08:00</published><updated>2026-11-09T04:24:34.866-08:00</updated><title type='text'>CMS Pulls Algorithmic Lab Tests Off the CLFS: The CY2027 SaMS Rules, Decoded  </title><summary type="text">&amp;nbsp;
CMS Pulls Algorithmic Lab Tests Off the CLFS: The CY2027 SaMS Rules, Decoded
Wednesday, November 4, 2026
AI CORNER [New replacement article, Claude, issued Nov 9]
OPPS final rule:https://www.federalregister.gov/documents/2026/11/06/2026-22739/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment&amp;nbsp;
PFS final rule:https://www.federalregister.gov/</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/8689745595459448191'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/8689745595459448191'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/cms-pulls-algorithmic-lab-services-off.html' title='CMS Pulls Algorithmic Lab Tests Off the CLFS: The CY2027 SaMS Rules, Decoded  '/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhq9A1fSnf7BVeYOYkOHPn60l4FoVfsbeRyCozTy2pq1NZJxtOrZAc7mUUFJbrNSOOpZ9cK7hlm55KBwqrxyWoMagvp8evfWREiQojs5eaXpWlBZZseRroar9LdDWEPmGdNJqUV8re2aw58-mcKcJ2EacPcfS8yViiNVrqrCT5apWMmZT0301sKQ2X2gLU/s72-w358-h471-c/image.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-4372462662192434625</id><published>2026-11-04T14:56:00.357-08:00</published><updated>2026-11-04T22:36:55.629-08:00</updated><title type='text'>Why Some Genomics Labs Reach Financial &quot;Escape Velocity&quot; - But Many Don&#39;t</title><summary type="text">Recently, Merck KGaA annnounced it was acquiring BioTechne for over $11 billion dollars.&amp;nbsp; BioTechne&#39;s management has been strong - that&#39;s up from a $5B valuation about ten years ago.&amp;nbsp; So the C-level team knew what it was doing.But, if you look through a genomics lens, along the way the same BioTechne C-suite bought Exosome Dx for $325M (2018) and sold it&amp;nbsp; for $15M (2025).&amp;nbsp; &amp;</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/4372462662192434625'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/4372462662192434625'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/why-some-genomics-labs-reach-financial.html' title='Why Some Genomics Labs Reach Financial &quot;Escape Velocity&quot; - But Many Don&#39;t'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhYL8Jtvoq9WXWFNVntw8sRRgOmhAXRXThyWm7weDQt106vbgkmREQT2qrudK2zXWef5fcpQHtvC8Y6uNvs1lQiO7QbWQh2vFWDhZ1Z9OG9TfQ6AYrfksDJgb3pY1uwozZs3TC6CrV2Du1egbruGInQJgRmH6vW49CCnMRDOmhoVNG4j5Dp2vkAVKbNHkk/s72-w353-h458-c/COVER%20Molecular%20diagnostics%20through%20the%20reimbursement%20maze.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-835366046107048180</id><published>2026-11-03T19:23:46.872-08:00</published><updated>2026-11-05T13:51:53.250-08:00</updated><title type='text'>Puzzling PAMA Pricing #2: Labs &amp; Losses Deep Dive</title><summary type="text">&amp;nbsp;You&#39;ve heard about how PAMA affects different groups - big labs, small labs, physician labs, and the labs of different medical specialties.Here, I used the assumption that PAMA pricing was pushed all the way - that tomorrow&#39;s prices were set at the actual medians found in PAMA data.&amp;nbsp; &amp;nbsp;My assumption was, we&#39;d see a normal or Gaussian distribution around the average price cut.&amp;nbsp;</summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/835366046107048180'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/835366046107048180'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/heard-about-how-pama-affects-different.html' title='Puzzling PAMA Pricing #2: Labs &amp; Losses Deep Dive'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgfxMQOkSdno2Pq8bPOXpFZtR21-x_2lZoRqYDGFCU8h5ene73Pntor_A69QOMZsGo8V7K9iUyfLXX0QX2TI9zucKbTaBdhBfdoXRvMC0OfLlEon_ELndQgVrst3CKOYCAfALEd8nIubqTu3-CC9ybt8DKo5HKg17YrEqNiTujGtRAyap1yDQHRPdNkzic/s72-w522-h258-c/15%20bins%20PAMA%20with%20LABELS%20in%204%20groups.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-8334321271827217759.post-477294119573661956</id><published>2026-11-03T15:09:23.707-08:00</published><updated>2026-11-03T15:28:56.159-08:00</updated><title type='text'>Puzzling PAMA Pricing Data #1.  Profiles of Six More Genetic Tests.</title><summary type="text">&amp;nbsp;In several blogs we&#39;ve gone past the median price discounts in various lab services.&amp;nbsp; We&#39;ve actually profiled the range of&amp;nbsp; reported PAMA raw price information - the shape of the marketplace.We showed that some codes, which have a right-sided isolated peak of high prices, can have as much as half of profit coming from those sky-high outliers. Here.Here, we do price profiles for </summary><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/477294119573661956'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/8334321271827217759/posts/default/477294119573661956'/><link rel='alternate' type='text/html' href='https://www.discoveriesinhealthpolicy.com/2026/11/puzzling-pama-pricing-data-1-profiles.html' title='Puzzling PAMA Pricing Data #1.  Profiles of Six More Genetic Tests.'/><author><name>Bruce</name><uri>http://www.blogger.com/profile/05149672650241065616</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgrEEbw6omcaq6R1PsCOcMlKKI00H_WVL7zQgA5AKbB5SqIMyKfplnp5FsnxLFNmL7QKISvQD3EM9MguLQdFtMMwxTsmuOxqWaU30XHIMuvdLXA1w-lwigFRmdmK_sBg/s220/_03A8604.BQ.JPG'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjOnP1eQKDH3AVNXLSNSQMP8bCdlSJtguqevlzLguPsJNPkJ7_zM0boS38zLwrXz2pqCwXoL108jA41w6T_2Qzia3KpWNlLfvg9exkRODfssp-3F8AK859DhbAivOp4bMMTtEdbJ53zECtfgQUQr8-UIQMXfcF0bvfUgyeXFvWdaAOjHO97DLAHrQfLEKA/s72-w504-h227-c/PAMA%206%20extra%20tests%20Y2Y%20six%20xextra%20genes%20jpeg%20of%20table.png" height="72" width="72"/></entry></feed>